Legend Biotech Corp (LEGN)vsVertex Pharmaceuticals Inc (VRTX)
LEGN
Legend Biotech Corp
$20.75
+7.62%
HEALTHCARE · Cap: $3.59B
VRTX
Vertex Pharmaceuticals Inc
$496.07
+2.49%
HEALTHCARE · Cap: $121.26B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 1005% more annual revenue ($12.59B vs $1.14B). VRTX leads profitability with a 35.0% profit margin vs -22.0%. VRTX earns a higher WallStSmart Score of 64/100 (C+).
LEGN
Hold36
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LEGN.
Margin of Safety
+50.1%
Fair Value
$971.64
Current Price
$496.07
$475.57 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 56.5% year-over-year
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Weak financial health signals
ROE of -25.9% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LEGN
The strongest argument for LEGN centers on Revenue Growth. Revenue growth of 56.5% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : LEGN
The primary concerns for LEGN are EPS Growth, Piotroski F-Score, Return on Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
LEGN profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
LEGN carries more volatility with a beta of 0.34 — expect wider price swings.
LEGN is growing revenue faster at 56.5% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 36/100), backed by strong 35.0% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Legend Biotech Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in North America and internationally.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?